S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
NASDAQ:CYTO

Altamira Therapeutics Stock Forecast, Price & News

$1.69
0.00 (0.00 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.66
$1.72
50-Day Range
$1.60
$3.11
52-Week Range
$0.78
$6.60
Volume
48,594 shs
Average Volume
2.25 million shs
Market Capitalization
$19.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.09
30 days | 90 days | 365 days | Advanced Chart
Receive CYTO News and Ratings via Email

Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Altamira Therapeutics logo

About Altamira Therapeutics

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTO
Employees
9
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.57 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$19.33 million
Next Earnings Date
N/A
Fiscal Year End
N/A
Optionable
Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1366th out of 1,372 stocks

Pharmaceutical Preparations Industry

663rd out of 669 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Altamira Therapeutics (NASDAQ:CYTO) Frequently Asked Questions

What stocks does MarketBeat like better than Altamira Therapeutics?

Wall Street analysts have given Altamira Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Altamira Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Altamira Therapeutics?

Altamira Therapeutics saw a decline in short interest in October. As of October 15th, there was short interest totaling 20,300 shares, a decline of 51.9% from the September 30th total of 42,200 shares. Based on an average trading volume of 489,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.3% of the shares of the company are short sold.
View Altamira Therapeutics' Short Interest
.

Who are Altamira Therapeutics' key executives?

Altamira Therapeutics' management team includes the following people:
  • Thomas Meyer, Chairman & Chief Executive Officer
  • Elmar Schärli, Chief Financial Officer
  • Samuel A. Wickline, Chief Scientific Officer
  • Andrea Vondraskova, Medical Director

What is Altamira Therapeutics' stock symbol?

Altamira Therapeutics trades on the NASDAQ under the ticker symbol "CYTO."

How do I buy shares of Altamira Therapeutics?

Shares of CYTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Altamira Therapeutics' stock price today?

One share of CYTO stock can currently be purchased for approximately $1.69.

How much money does Altamira Therapeutics make?

Altamira Therapeutics has a market capitalization of $19.33 million.

How many employees does Altamira Therapeutics have?

Altamira Therapeutics employs 9 workers across the globe.

What is Altamira Therapeutics' official website?

The official website for Altamira Therapeutics is www.aurismedical.com.

Where are Altamira Therapeutics' headquarters?

Altamira Therapeutics is headquartered at Bahnhofstrasse 21, Zug, Zug 6300.

How can I contact Altamira Therapeutics?

Altamira Therapeutics' mailing address is Bahnhofstrasse 21, Zug, Zug 6300. The company can be reached via phone at (441) 295-5950 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.